These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 427801

  • 21. [Disruption of DNA synthesis and structure of mouse L1210 leukemia cells, sensitive and resistant to 1-methyl-1 nitrosourea and 1,3-bis(2-chloroethyl)-1-nitrosourea in vivo].
    Kukushkina GV, Peretolchina NM, Minenkova EA, Verovskiĭ VN, Sof'ina ZP.
    Biokhimiia; 1984 Jul; 49(7):1189-98. PubMed ID: 6477985
    [Abstract] [Full Text] [Related]

  • 22. A biochemical and pharmacological study of therapeutic synergism with 5-fluorouracil plus cyclophosphamide in murine L1210 leukemia.
    Fernandes DJ, Klubes P.
    Cancer Res; 1979 Apr; 39(4):1396-404. PubMed ID: 421224
    [No Abstract] [Full Text] [Related]

  • 23. Dose-dependent cytokinetic changes following 1-beta-D-arabinofuranosylcytosine and hydroxyurea in L1210 and S-180 in vivo.
    Straus MJ, Moran RE.
    Cell Tissue Kinet; 1978 Sep; 11(5):529-42. PubMed ID: 299719
    [Abstract] [Full Text] [Related]

  • 24. Synergistic action of 5-aza-2'-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells.
    Momparler RL, Veselý J, Momparler LF, Rivard GE.
    Cancer Res; 1979 Oct; 39(10):3822-7. PubMed ID: 476619
    [Abstract] [Full Text] [Related]

  • 25. Use of cell-cycle information in the preparation of drug combinations: results with cytosine arabinoside plus actinomycin D1,2.
    Bhuyan BK, Fraser TJ, Day KJ.
    Cancer Treat Rep; 1976 Dec; 60(12):1813-8. PubMed ID: 1036090
    [Abstract] [Full Text] [Related]

  • 26. Effect of carbamoylation on the repair of nitrosourea-induced DNA alkylation damage in L1210 cells.
    Heal JM, Fox PA, Schein PS.
    Cancer Res; 1979 Jan; 39(1):82-9. PubMed ID: 153789
    [No Abstract] [Full Text] [Related]

  • 27. Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents.
    Gale GR, Atkins LM, Meischen SJ, Smith AB, Walker EM.
    Cancer Treat Rep; 1977 Jan; 61(3):445-50. PubMed ID: 872142
    [Abstract] [Full Text] [Related]

  • 28. Cell-kill kinetics of several S-phase-specific drugs.
    Bhuyan BK, Fraser TJ, Gray LG, Kuentzel SL, Neil GL.
    Cancer Res; 1973 Apr; 33(4):888-94. PubMed ID: 4735241
    [No Abstract] [Full Text] [Related]

  • 29. Biochemical rationales for the selection of combinations of chemotherapeutic agents.
    Bono VH.
    Cancer Chemother Rep 2; 1974 Mar; 4(1):131-6. PubMed ID: 4826492
    [No Abstract] [Full Text] [Related]

  • 30. Effects of 5-fluorouracil on 5-fluorodeoxyuridine 5'-monophosphate and 2-deoxyuridine 5'-monophosphate pools, and DNA synthesis in solid mouse L1210 and rat Walker 256 tumors.
    Klubes P, Connelly K, Cerna I, Mandel HG.
    Cancer Res; 1978 Aug; 38(8):2325-31. PubMed ID: 667828
    [No Abstract] [Full Text] [Related]

  • 31. DNA damage and repair in mouse leukemia L1210 cells treated with nitrogen mustard, 1,3-bis(2-chloroethyl)-1-nitrosourea, and other nitrosoureas.
    Ewig RA, Kohn KW.
    Cancer Res; 1977 Jul; 37(7 Pt 1):2114-22. PubMed ID: 558823
    [No Abstract] [Full Text] [Related]

  • 32. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.
    Skipper HE, Schabel FM, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, Brockman RW.
    Cancer Chemother Rep; 1970 Dec; 54(6):431-50. PubMed ID: 5527023
    [No Abstract] [Full Text] [Related]

  • 33. Effects of tryptophan deprivation on L1210 cells in culture.
    Woolley PV, Dion RL, Bono VH.
    Cancer Res; 1974 May; 34(5):1010-4. PubMed ID: 4856777
    [No Abstract] [Full Text] [Related]

  • 34. An in vitro assay for evaluating chemosensitivity of leukaemia cells: preclinical studies.
    Menconi E, Lepri E, Bonmassar E, Frati L, Barzi A.
    Int J Tissue React; 1986 May; 8(6):485-92. PubMed ID: 3793386
    [Abstract] [Full Text] [Related]

  • 35. Resting cells in L1210 and JB-1 ascites tumors with special emphasis on recycling.
    Hartmann NR, Dombernowsky P, Bichel P.
    Cancer Treat Rep; 1976 Dec; 60(12):1861-70. PubMed ID: 1026340
    [No Abstract] [Full Text] [Related]

  • 36. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
    Reddy LH, Dubernet C, Mouelhi SL, Marque PE, Desmaele D, Couvreur P.
    J Control Release; 2007 Dec 04; 124(1-2):20-7. PubMed ID: 17878060
    [Abstract] [Full Text] [Related]

  • 37. Cytotoxicity of methylglyoxal bis(guanylhydrazone) in combination with alpha-difluoromethylornithine against HeLa cells and mouse L1210 leukemia.
    Sunkara PS, Prakash NJ, Chang CC, Sjoerdsma A.
    J Natl Cancer Inst; 1983 Mar 04; 70(3):505-9. PubMed ID: 6403743
    [No Abstract] [Full Text] [Related]

  • 38. N-trifluoroacetyladriamycin-14-valerate: additional mouse antitumor and toxicity studies.
    Parker LM, Hirst M, Israel M.
    Cancer Treat Rep; 1978 Jan 04; 62(1):119-27. PubMed ID: 272230
    [No Abstract] [Full Text] [Related]

  • 39. [Cytokinetic effects of oridonin on leukemia L1210 cells].
    Wang MY, Lin C, Zhang TM.
    Zhongguo Yao Li Xue Bao; 1985 Sep 04; 6(3):195-8. PubMed ID: 2943126
    [No Abstract] [Full Text] [Related]

  • 40. Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model.
    Sirotnak FM, Donsbach RC, Moccio DM, Dorick DM.
    Cancer Res; 1976 Dec 04; 36(12):4679-86. PubMed ID: 1087182
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.